Lianhuan Pharmaceutical's controlling subsidiary, Changle Pharmaceutical, has received the Drug Registration Certificate for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (I/II/III) issued by the National Medical Products Administration. The drug was approved as a Category 4 chemical drug, deemed to have passed the consistency evaluation, with specifications including 10 mg/1000 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg, for use in improving glycemic control in adult patients with type 2 diabetes. The company stated that this approval will further enrich its product line, but it is not expected to have a significant impact on near-term performance, and the production and sales of the product are subject to uncertainties due to industry policies and market changes.
Jiangsu Lianhuan Pharmaceutical Co LtdSubsidiary obtained drug registration certificate for a new product, enriching product line.
Received Drug Registration Certificate for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets.